logo
  

Stock Alert: Concert Pharmaceuticals Tanks 40%

Shares of Concert Pharmaceuticals, Inc. (CNCE) are losing nearly 40% on Monday morning after the drug company said CTP-692 study in schizophrenia fails to meet primary or secondary endpoint.

CNCE is currently trading at $6.28, down $4.19 or 39.97%, on the Nasdaq.

Concert Pharmaceuticals announced that its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint or other secondary endpoints. CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMDA receptor.

"Unfortunately, we didn't see the results we hoped for to support continuation of this program. Going forward, we will focus our internal resources on the advancement of CTP-543, which is currently in Phase 3 evaluation for the treatment of alopecia areata, and evaluation of additional pipeline candidates," stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tech major Google, owned by Alphabet Inc., has unveiled a new chatbot tool called Bard. The experimental conversational artificial intelligence or AI service is built on a large language model, powered by the company's Language Model for Dialogue Applications or LaMDA. DuPont reported Tuesday a profit from continuing operations for the fourth quarter that decreased 37 percent from last year, hurt by charges related to the intended Rogers transaction. Both adjusted earnings per share from continuing operations and quarterly net sales missed analysts' expectations. The company also provide guidance for the first quarter and the full-year 2023. Shares of Siemens Energy AG were losing around 5 percent in German trading after the energy development company reported Tuesday wider net loss in its first quarter and adjusted fiscal 2023 forecast to now expect net loss same as the prior year. Revenues and orders for the quarter, however, climbed and the company maintained its fiscal 2023 revenue forecast.
RELATED NEWS
Follow RTT